Lumen Bioscience
Developer of a spirulina-based platform for expressing and delivering therapeutic proteins. The company engineers Arthrospira (spirulina) to produce high-yield biologics intended for oral or topical delivery, and operates integrated discovery, development, GMP manufacturing, and clinical operations to advance candidates from preclinical work through clinical trials.
Industries
Nr. of Employees
medium (51-250)
Patents
Leptin compositions and methods of making and using the same to support weight loss and/or maintenance
US-12466883-B1
View Details
Leptin compositions and methods of making and using the same to support weight loss and/or maintenance
US-12466883-B1
View DetailsProducts
Orally delivered biologic cocktail for C. difficile (LMN-201)
Oral biologic cocktail designed to treat C. difficile colitis; listed in Phase 2/3 clinical stage on company pipeline.
Oral biologic cocktail for inflammatory bowel disease (IBD)
Spirulina-derived biologic cocktail intended for Crohn’s disease and ulcerative colitis; described as preclinical with rationale for oral, low-cost delivery.
Antibody cocktail for gastroenteritis (field POC 2026)
Antibody cocktail designed to neutralize common GI pathogens; early ileostomy PK and field studies reported, with a proof-of-concept study planned.
Intranasal biologic for viral respiratory infections
Intranasal biologic intended to support nasal barrier function and reduce viral attachment and transmission; reported to be in Phase 1 development.
Intranasal vaccine candidate for malaria
Exploratory/preclinical intranasal vaccine program targeting Plasmodium infection; intended as a low-cost, stable adjunct for endemic regions.
Spirulina-derived protein ingredient (LMN-0801)
Research-stage, spirulina-derived protein ingredient produced by the oral protein platform; described as ongoing research.
Orally delivered biologic cocktail for C. difficile (LMN-201)
Oral biologic cocktail designed to treat C. difficile colitis; listed in Phase 2/3 clinical stage on company pipeline.
Oral biologic cocktail for inflammatory bowel disease (IBD)
Spirulina-derived biologic cocktail intended for Crohn’s disease and ulcerative colitis; described as preclinical with rationale for oral, low-cost delivery.
Antibody cocktail for gastroenteritis (field POC 2026)
Antibody cocktail designed to neutralize common GI pathogens; early ileostomy PK and field studies reported, with a proof-of-concept study planned.
Intranasal biologic for viral respiratory infections
Intranasal biologic intended to support nasal barrier function and reduce viral attachment and transmission; reported to be in Phase 1 development.
Intranasal vaccine candidate for malaria
Exploratory/preclinical intranasal vaccine program targeting Plasmodium infection; intended as a low-cost, stable adjunct for endemic regions.
Spirulina-derived protein ingredient (LMN-0801)
Research-stage, spirulina-derived protein ingredient produced by the oral protein platform; described as ongoing research.
Expertise Areas
- Oral biologics development
- Microalgal biomanufacturing
- Protein engineering and antibody discovery
- GMP biologics production and downstream processing
Key Technologies
- Microalgal expression systems (spirulina)
- CRISPRi and genetic engineering
- Phage panning/display
- Photobioreactors and large-scale cultivation
News & Updates
Company-published report of preliminary cohort results showing clinical cures for C. difficile infection.
Article covering defense funding and potential cost-reduction implications for antibody manufacturing using the company's platform.
Announcement of a $30M Series C extension to support platform and pipeline development.
Company-published report of preliminary cohort results showing clinical cures for C. difficile infection.
Article covering defense funding and potential cost-reduction implications for antibody manufacturing using the company's platform.
Announcement of a $30M Series C extension to support platform and pipeline development.